

June 20, 2011

RRS, BS, RSS, TOS, PB, TES, MOAS, KAP, FL, CP  
SOB, AW, POM, CBM, RMS

**Redacted as Non-Purdue Material**

June 21, 2011

RDS, BS, RBS, PB

TES, CP, VL, MOAS, KAS

CBM, SOB, DAK, EBM, R. W. J. L. A.

**Redacted as Non-Purdue Material**

June 22, 2011

RSS, BS, RAS, TSS, MOAS, VL, CP, IB, JAS, KAS

US Presentation

**Redacted as Non-Purdue Material**

**Redacted as Non-Purdue Material**

**Redacted as Non-Purdue Material**

*June 23, 2011*

*RRS, BS, RSS, JOS, PB*

*CP, VL, KAS, TES, MOAS*

*SOB, CBM, et al*

**Redacted as Non-Purdue Material**

**Redacted as Non-Purdue Material**

June 24, 2011

CP, JL, KAS, HOAS, FSC, TES

RSS, PB, RRS, BS, TOS

SOS, et al.

Ernst & Jorg

Done ✓

**Redacted as Non-Purdue Material**

**Redacted as Non-Purdue Material**



**Redacted as Non-Purdue Material**

Vin Tox Pharmaceuticals

MOAB, KAS, TL, CP, FES, ISL

PS, VAS, ESS, BS, RES

Approved

**Attorney-Client Privilege**

# Attorney-Client Privilege

Oncology Market

XXX

ON

NEXT

AB-N04

AS WELL

XXX

Should we enter oncology market in US and  
if so what about Atlas?

• late stage acquisition seems doable

• market we want to be cash flow positive  
by 2014• can risk - look for cash flow positive  
acquisition

TSS - defer

KAS - defer

MOAS -

RES - defer

CP - take a look

TOS - take a look

ESS - take a look

TL - defer

• Done by global unit

• be ready for 2013/2014

DEFER

PPLI Q2 \$200 M DISTRIBUTION

APPROVED

RES, SS, ESS, TOS, PB

TSS, KAS, TSE, MOAS, TL, CP

# Redacted as Non-Purdue Material

US Budget Request

\*1.1 gross sales short-fall  
\*800M short as bottom line

No change to Budget

Increase lead count okay but do it by  
attrition or other cost savings measures so  
the bottom line of the MYS is not adversely  
impacted

RES, RSS, VOS,  
16, TES, KAS,  
MORS, CO, JL  
18L

Approved

\* Attrition to hit hires, but keep your total  
lead count out for spend the same

# Redacted as Non-Purdue Material